U.S. market Closed. Opens in 1 day 21 hours 21 minutes

MAIA | MAIA Biotechnology, Inc. Stock Overview

(Stock Exchange: AMEX)
Day's Range 1.8134 - 1.9200
52 Week Range 1.2400 - 5.99
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 66,069
Average Volume 315,215
Shares Outstanding 25,332,070
Market Cap 46,864,330
Sector Healthcare
Industry Biotechnology
IPO Date 2022-07-28
Valuation
Profitability
Growth
Health
P/E Ratio -1.38
Forward P/E Ratio N/A
EPS -1.34
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 13
Country USA
Website MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
*Chart delayed
Analyzing fundamentals for MAIA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see MAIA Fundamentals page.

Watching at MAIA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on MAIA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙